Objectives: To study the relationship between diabetes mellitus (DM) and left ventricular (LV) function on outcomes following percutaneous coronary intervention (PCI).
There has been an increase in the proportion of patients with established DM undergoing percutaneous coronary intervention (PCI) [5] . Left ventricular systolic dysfunction (LVSD) is known to adversely impact early clinical outcomes following PCI for all indications [6] .
Although the importance of diabetes in the development of LVSD (and subsequent heart failure) is recognized, the interplay between these factors in patients undergoing PCI is less well established.
The BCIS database includes virtually all PCI performed in the UK NHS and as such has the scale to estimate the influence of important factors on outcomes, including within subgroups. Our aim was to analyze outcomes for patients defined by their diabetes status (present or absent, and by treatment of diabetes) within different grades of LV function following PCI. We have focused the analysis on early outcomes at 30-days.
| M E TH ODS
We conducted a retrospective cohort study of all patients in England and Wales who received PCI in the UK between 2006 and 2013. BCIS collected information related to PCI procedures in the UK. National Institute for Cardiac Outcomes Research (NICOR) managed the data collection and in 2015, the BCIS-NICOR database collected >99% of all PCI procedures performed. The BCIS-NICOR database contains 113 clinical, procedural, and outcomes variables; a set of standard definitions are available publicly in the NICOR website [7] . The BCIS standard dataset defines good LV function as LVEF > 50%, moderately impaired as an LVEF of 30%-50%, and poor LV function as <30%. The definition allows LV function to be derived from echocardiography nuclear cardiology studies, cardiac magnetic resonance imaging, or invasive left ventriculography.
Diabetes status and type of diabetes were recorded by the PCI operator at the time of procedure as no diabetes, diabetes (diet controlled), diabetes (tablet controlled), or diabetes (insulin controlled). All entries are linked to mortality data recorded in the Medical Research Information Services via their unique identifier NHS number along with in-hospital major adverse cardiovascular events (MACE) and bleeding [8] [9] [10] . days, in-hospital MACE, and in-hospital bleeding. MACE was defined by the composite of re-infarction, repeat PCI, and death in-hospital. Inhospital bleeding was defined by a composite of gastrointestinal bleeding, cerebrovascular bleeding, receipt of blood or platelet transfusion, retroperitoneal bleed or bleeding requiring surgical intervention.
Data analysis was performed using Stata 14. Descriptive statistics were presented according to diabetes status and LV ejection fraction.
One-way analysis of variance was used to determine whether there were difference among groups for continuous variables and chi-squared test was used to determine whether there were difference among groups for 
| Crude outcomes by LV function, diabetes, and subtype of diabetes
There was a trend for poorer unadjusted outcome with increasing grades of LV dysfunction in patients with both DM and non-DM (Table 2) . Across all grades of LV dysfunction, there was a higher crude mortality rate in DM patients and within the DM cohort, insulinrequiring diabetes had worse outcomes as compared to diet and tablet controlled DM (Table 2) .
| Effect of LV function on outcome
Increasing degrees of LV dysfunction were associated with a poorer prognosis at 30 days following PCI (Table 3 , Figure 3A ,B Figure 4A -C).
No clear subgroup differences were noted for the other outcomes of in-hospital bleeding or MACE.
When outcome was assessed in relation to LV function, the trend for a reduced influence of diabetes with reduction in LV function was again noted predominantly in insulin-treated patients ( 
| D I SCUSSION
This analysis of 260,726 patients from the UK national dataset confirmed the impact of LV systolic dysfunction on mortality at 30 days after PCI. Furthermore, this study showed that the relative influence of DM (in particular insulin-requiring patients) on early mortality after PCI was diminished in patients with the lowest LV ejection fractions. For the cohort as a whole, DM was associated with a modest but consistent increase in mortality at 30 days in all grades of LV dysfunction.
Previous analyses of the UK dataset have confirmed the strong relationship between reduced LV function and PCI outcomes [6] . Studies in large populations have suggested that diabetes is an important risk factor for development of heart failure [4, 11] , and worse long-term outcome in patients with established heart failure [4] . In patients presenting acutely with STEMI, DM is associated with increased incidence of subsequent heart failure, and worse outcome [12] . Following PCI, outcomes in patients with DM were poorer in the early stent [13] , and pre-DES eras [14] . More recently DM was found to be a significant predictor of worse longer-term outcomes following PCI, particularly in incomplete revascularization [15] , and following primary PCI [16, 17] .
Our data revealed that within the diabetic population, insulin requiring DM was associated with poorer outcomes regardless of LV function. Diabetic patients had worse risk factor profiles with increased incidence of hypertension and hyperlipidemia, increasing the likelihood of concomitant microvascular disease. This cumulative disease burden significantly affects the risk of future cardiovascular disease in patients with type 2 DM both in the absence of known coronary disease [18] and following revascularization (PCI or CABG) [19, 20] . Both iatrogenic hyperinsulinemia and the endogenous hyperinsulinemic state present in type 2 diabetes can promote pro-inflammatory responses affecting progression of atherogenesis and disrupting endothelial function along with increased platelet aggregation, increasing the risk of MACE events [21] [22] [23] . Large contemporary DES trials support this observation, with increased rate of target lesion revascularization (TLR) shown in insulin requiring patients [24, 25] . Our analysis of this very large real-world cohort confirms the association between DM and a worse early PCI outcome in a contemporary population, treated predominantly with DES.
In the setting of severe LVSD, we found DM to be less important at predicting early PCI outcomes. It should be noted that DM was not protective in LVSD, and the worst crude outcomes following PCI are in the group of patients with poor LV and DM with the 12.7% of insulinrequiring DM and poor LV having the highest mortality at 30 days of any subgroup. The combination of DM and severe LVSD was associated with greater proportions of previous CABG, previous MI, renal disease, and lower rates of radial access, which may exert independent effects. However, after adjustment for known confounding factors the apparent doubling of risk in normal LV function patients seen with insulin requiring DM was markedly lower in patients with severe LVSD.
The association between LV function and adverse mortality outcomes, and the differential association of poor LV function on mortality across different indications for PCI, is recognized [6] . Impaired physiological reserve reduces the tolerability of hemodynamic or ischemic compromise during PCI whilst, in the long-term, impaired LV function increases mortality from progressive heart failure and ventricular arrhythmias. Including LV function into the SYNTAX II score significantly improved the models' ability to predict 4-year outcomes whilst diabetic status did not [26] . Although it was noted that more "severe" diabetes, in particular the presence of proteinuria, may be captured through variables such as creatinine clearance [27] .
In summary, this large retrospective analysis confirms the adverse impact of poor LV function on patients undergoing PCI. Importantly, this study suggests that the impact of DM on outcomes after PCI is more pronounced in the presence of preserved LV function and declines progressively with worsening LV function. In developing risk models for patients undergoing PCI (such as SYNTAX), the findings from this study can provide information to improve predictive accuracy. The findings will help inform physicians and patients about potential risks of PCI in patients with DM and LV dysfunction.
| Strengths
The Mortality tracking was complete for all patients included, and provides a robust and unbiased end-point. The BCIS dataset includes highrisk patients who are often excluded from randomized controlled trials.
As such this national analysis represents the only study of the influence of DM on the prognostic impact of LV function on PCI outcomes to date.
| Limitations
Only half of all patients who underwent PCI had LV function documented. The exclusion of patients without assessment of LV function is a potential source of bias in determining patient outcomes, although the distribution of LV function is similar to those reported in previous analyses and the proportion of missing data for LV function was numerically similar irrespective of diabetes status (50.6% in patients without DM and 47.5% in patients with DM [28, 29] provision of such therapies in patients with poor LV function may contribute to the differences in outcomes that we report. As a routinely collected national registry, end points are not specifically adjudicated. MACE and bleeding events are largely self-reported and may vary between institutions for completeness [31] . The aim of this analysis was to assess the impact of DM on short-term PCI outcomes. We did not have longer-term outcome data available, although this would be of interest in a future study. Whilst it is well known that effective management of DM is associated with improved patient outcomes, the BCIS dataset does not collect data on either hypoglycemic agents or glycemic control [32] . We were not able to account for the potentially important effect of undiagnosed/ untreated diabetes. Such patients would have been classified as nondiabetic and may have resulted in an underestimation of the effect of diabetes on clinical outcome. Additionally, the dataset does not routinely collect data on the date of DM onset or the presence of diabetes-related complications and, whilst it is well known that effective management of DM is associated with patient outcomes, the BCIS database does not collect data on either hypoglycemia agents or glycemic control.
Finally, our analysis is of observational data and cannot be used to infer causal relationships; despite the inclusion of multiple procedural and demographic factors, unmeasured confounders might account for some differences of outcomes observed.
| C ONC LUSI ON
Our analysis of 260,726 UK patients undergoing PCI procedures in the DES era suggests that DM is associated with worse outcomes following all PCI in all grades of LV dysfunction. The independent prognostic impact of diabetes is strongest in patients with normal LV function but reduces in patients with severe LV systolic dysfunction.
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